Prostate cancer is an exemplar of an enhancer-binding transcription factor-driven disease.
The androgen receptor (AR) enhanceosome complex comprised of chromatin and
epigenetic coregulators assembles at enhancer elements to drive disease progression. The
paralog lysine acetyltransferases p300 and CBP deposit histone marks that are associated
with enhancer activation. Here, we demonstrate that p300/CBP are determinant cofactors of
the active AR enhanceosome in prostate cancer. Histone H2B N-terminus multisite lysine …